BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Vacc-4x (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Proof of concept; Therapeutic Use
- Acronyms BIOSKILL
- Sponsors Bionor Pharma
- 07 Jun 2017 Biomarkers information updated
- 13 Mar 2016 Status changed from planning to recruiting as reported by European Clinical Trials Database.
- 21 Dec 2015 According to Bionor media release, company has filed clinical trial applications in the United Kingdom, Germany and Denmark.